Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003136 | 0.86 | YTHDC1 (0.39) | YTHDC1ATRCYP3A4HDAC1 | |
| SCHEMBL9937975 | 0.85 | YTHDC1 (0.38) | YTHDC1ATRCYP3A4HDAC1NT5E | |
| SCHEMBL10008246 | 0.85 | YTHDC1 (0.38) | YTHDC1ATRCYP3A4HDAC1 | |
| SCHEMBL21523565 | 0.79 | YTHDC1 (0.34) | YTHDC1ATRHDAC1 | |
| SCHEMBL30076448 | 0.79 | YTHDC1 (0.34) | YTHDC1ATRHDAC1NT5E | |
| SCHEMBL9936683 | 0.79 | YTHDC1 (0.34) | YTHDC1ATRHDAC1NT5E | |
| SCHEMBL9937867 | 0.78 | HDAC1 (0.37) | YTHDC1ATRHDAC1NT5E | |
| SCHEMBL19206330 | 0.77 | YTHDC1 (0.39) | YTHDC1ATRCYP3A4HDAC1NT5E | |
| SCHEMBL2673005 | 0.77 | YTHDC1 (0.41) | YTHDC1ATRCYP3A4HDAC1NT5E | |
| SCHEMBL30471093 | 0.76 | YTHDC1 (0.38) | YTHDC1ATRCYP3A4HDAC1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| EP-3053925-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2813506-B1 | Tricyclic PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2813506-A1 | Tricyclic PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | YTHDC1 4755/4885ATR 478/4885CYP3A4 1099/4885 |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | YTHDC1 4766/4885ATR 507/4885CYP3A4 1190/4885 |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | YTHDC1 4766/4885ATR 507/4885CYP3A4 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.